Protara Therapeutics (TARA) Shares Outstanding (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Shares Outstanding (Entity) of $55.1 million for Q1 2026, up 42.71% year-over-year from $38.6 million in Q1 2025, and up 28.53% quarter-over-quarter from $42.8 million in Q4 2025.
Protara Therapeutics (TARA) Shares Outstanding (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Shares Outstanding (Entity) for 14 consecutive years, with $55.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 42.71% year-over-year to $55.1 million; the TTM figure through Mar 2026 stood at $55.1 million (up 42.71% YoY), while the FY2025 annual figure was $42.8 million, up 108.01% from the prior year.
- Shares Outstanding (Entity) improved to $55.1 million in Q1 2026 per TARA's latest filing, from $42.8 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $55.1 million in Q1 2026 and bottomed at $11.3 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $22.2 million across 5 years, with a median of $11.4 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 0.21% — and 2025, when it jumped 237.4%.
- Protara Therapeutics' Shares Outstanding (Entity) stood at $11.3 million in 2022, then rose by 0.87% to $11.4 million in 2023, then soared by 81.2% to $20.6 million in 2024, then soared by 108.01% to $42.8 million in 2025, then rose by 28.53% to $55.1 million in 2026.
- Business Quant data shows TARA's Shares Outstanding (Entity) at $55.1 million in Q1 2026, $42.8 million in Q4 2025, and $38.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 61.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.01 Mn |
| Mar 31, 2026 | 57.54 Mn |
| Dec 31, 2025 | 42.84 Mn |
| Sep 30, 2025 | 42.27 Mn |
| Jun 30, 2025 | 42.27 Mn |
| Mar 31, 2025 | 40.71 Mn |
| Dec 31, 2024 | 20.59 Mn |
| Sep 30, 2024 | 22.33 Mn |
| Jun 30, 2024 | 21.23 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Dec 31, 2023 | 11.33 Mn |
| Sep 30, 2023 | 11.35 Mn |
| Jun 30, 2023 | 11.31 Mn |
| Mar 31, 2023 | 11.30 Mn |
| Dec 31, 2022 | 11.26 Mn |
| Sep 30, 2022 | 11.27 Mn |
| Jun 30, 2022 | 11.26 Mn |
| Mar 31, 2022 | 11.25 Mn |
| Dec 31, 2021 | 11.23 Mn |
| Sep 30, 2021 | 11.24 Mn |